Menquadfi (Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi)

Menquadfi is a meningococcal C conjugate vaccine used to prevent invasive disease caused by Neisseria meningitidis serogroup C.

• Invasive meningococcal disease (serogroup C): provides active immunity to reduce risk of severe infection.
• Travel to endemic regions: lowers chance of acquiring serogroup C meningococcal infection during travel.
• Outbreak control in communities: contributes to herd immunity and helps contain serogroup C outbreaks.
• Routine immunization programs: supports public health strategies for preventing meningococcal disease in eligible populations.

• The vaccine contains polysaccharide from Neisseria meningitidis serogroup C covalently linked to tetanus toxoid, creating a conjugate that is recognized by the immune system as a protein antigen. This conjugation enables T‑cell dependent activation, leading to robust B‑cell proliferation and production of high‑affinity anti‑capsular antibodies that neutralize the bacteria. The generated antibodies promote opsonophagocytic killing and prevent bacterial colonization of the nasopharynx.

Menquadfi, like other injectable vaccines, may be associated with local and systemic reactions.

Common Side Effects

• Injection site pain: mild to moderate soreness at the injection site.
• Redness or swelling: transient erythema or edema around the injection area.
• Fever: low-grade temperature elevation within 24‑48 hours.
• Headache: mild headache occurring shortly after vaccination.
• Fatigue: temporary feeling of tiredness or weakness.
• Myalgia: muscle aches near the injection site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare neurologic disorder characterized by muscle weakness.
• Seizures: infrequent occurrence of convulsions post‑vaccination.
• Severe hypotension: marked drop in blood pressure following injection.
• Acute allergic edema: swelling of face, lips or airway.
• Immune thrombocytopenia: rare drop in platelet count.

Before administering Menquadfi, healthcare providers should consider several precautionary measures.

• Pregnancy: safety has not been established; evaluate risk‑benefit ratio.
• Allergy: avoid in individuals with known hypersensitivity to tetanus toxoid or any vaccine component.
• Immunocompromised patients: may exhibit reduced immune response; monitor effectiveness.
• Fever or acute illness: postpone vaccination until the condition resolves.
• Concomitant vaccines: follow recommended intervals when co‑administering with other immunizations.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccine interactions are generally limited, but certain agents may affect immunogenicity or safety.

Major Interactions (Avoid)

• Live bacterial vaccines: do not administer simultaneously with Menquadfi.
• Severe allergic reaction to any component: contraindicates use of the vaccine.

Moderate Interactions (Monitor Closely)

• Immunoglobulin therapy: may diminish antibody response if given within 4 weeks.
• Antipyretic medications: can mask post‑vaccination fever, monitor patient symptoms.
• Immunosuppressive drugs: may reduce vaccine efficacy; assess immune status.
• Blood products: transfusions within 48 hours may interfere with immune response.